Non-small cell lung cancer is a more common lung malignancy in clinical practice, accounting for approximately 80% of lung cancers, and only 30% of them have a chance of surgery when detected, and 70% of them are in advanced or locally advanced stages, at which time only non-surgical treatment can be used. In the past, chemotherapy and radiotherapy were the first choice of treatment, but the latest research shows that worldwide multicenter clinical studies have demonstrated that for non-small cell lung cancer patients with epidermal growth factor (EGFR) mutations, the efficiency of ERSA (gefitinib) can reach 71% or higher (for different countries), with a median survival of 10 months, while the efficiency of paclitaxel combined with carboplatin chemotherapy The significance of this study is that for EGFR mutated NSCLC patients, first-line treatment with ERSA is the best choice, and it has made a leap forward in the treatment of advanced NSCLC.